A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

  • End date
    Jun 1, 2028
  • participants needed
  • sponsor
    Hoffmann-La Roche
Updated on 6 September 2021
Reference Study ID Number: WA41937 http://www.roche.com/about_roche/roche_worldwide.htm
Primary Contact
Hospital Alberto Sabogal Sologuren (2.9 mi away) Contact
+79 other location


This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

Condition Primary Membranous Nephropathy
Treatment Tacrolimus, Methylprednisolone, Obinutuzumab, Acetaminophen, Diphenhydramine
Clinical Study IdentifierNCT04629248
SponsorHoffmann-La Roche
Last Modified on6 September 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening
Urinary protein-to-creatinine ratio (UPCR) >= 5 g/g from 24-hour urine collection despite best supportive care for >= 3 months prior to screening or UPCR >= 4 g/g despite best supportive care >= 6 months prior to screening
eGFR >= 40 mL/min/1.73m^2 or qualified endogenous creatinine clearance >= 40 mL/min/1.73m^2 based on 24-hour urine collection during screening
Other inclusion criteria may apply

Exclusion Criteria

Participants with a secondary cause of MN
Pregnancy or breastfeeding
Evidence of >= 50% reduction in proteinuria during the previous 6 months prior to randomization
Severe renal impairment, including the need for dialysis or renal replacement therapy
Type 1 or 2 diabetes mellitus
Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening
Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
Known active infection of any kind or recent major episode of infection
Major surgery requiring hospitalization within the 4 weeks prior to screening
Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening
Intolerance or contraindication to study therapies
Other exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note